THERAVECTYS Provides Update on Its Phase I/II Lentiviral Vector-Based Therapeutic Vaccine Trial

November 18, 2014 THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies, reports promising preliminary results in the first-ever vaccination trial conducted with lentiviral vectors. The randomized, placebo-controlled trial currently enrolls 38 HIV-positive patients under highly active antiretroviral therapy (HAART) in 12 clinical sites in France and Belgium and aims at comparing …

THERAVECTYS Files Suit in the U.S. Against Immune Design Corp

-Lawsuit raises claims of tortious interference with contractual relations,  -misappropriation of trade secrets, unfair competition and unjust enrichment# July 25th, 2014 THERAVECTYS announced that it filed a lawsuit against Seattle-based Immune Design Corp. (“IDC”) in the Delaware Court of Chancery and is seeking preliminary and permanent injunctive relief, as well as monetary damages. In its suit, THERAVECTYS raises claims of …